“Recombinant human erythropoietin (rHuEPO) reduces transfusion requirements in anaemia of prematurity”, Northern Int. Med. Coll. J., vol. 6, no. 2, pp. 53–56, May 2015, doi: 10.3329/nimcj.v6i2.23171.